A Pilot Study to Assess the Combination of Stereotactic Body Radiation Therapy and CDX-1127 in Modulating Local and Systemic T-cell Responses Against Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 05 May 2017
At a glance
- Drugs Varlilumab (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacodynamics
- Acronyms Prostate-04
- Sponsors Celldex Therapeutics Inc
- 10 Jun 2017 Biomarkers information updated
- 30 Nov 2016 Status changed from recruiting to discontinued.
- 17 Nov 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.